Looking inside the primary tumour: what drives immunotherapy response in renal cell carcinoma?

BMJ Oncology · Published 2026-07-01 · DOI 10.1136/bmjonc-2026-001195

Free full text

Authors (2)

Supriya Peshin, Ehab Takrori

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Peshin, S., Takrori, E. (2026). Looking inside the primary tumour: what drives immunotherapy response in renal cell carcinoma?. BMJ Oncology. https://doi.org/10.1136/bmjonc-2026-001195

Related articles

• Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection · BMJ Oncology · 2026 · Same journal
• Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences? · BMJ Oncology · 2026 · Same journal
• Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study · BMJ Oncology · 2025 · Same journal
• Understanding characteristics of contemporary cancer survival for modelling the cost-effectiveness of new interventions · BMJ Oncology · 2025 · Same journal
• Global determinants of cervical cancer outcomes: a health systems analysis · BMJ Oncology · 2026 · Same journal
• Evidence-based modelling and taxonomy of hospital-based cancer care coordination nurses’ roles and boundaries: an iterative multiphase convergent mixed study · BMJ Oncology · 2025 · Same journal
• BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials · BMJ Oncology · 2026 · Same journal
• Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II–III non-small cell lung cancer in Sri Lanka · BMJ Oncology · 2026 · Same journal
• Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges · BMJ Oncology · 2025 · Same journal
• Lost in translation: why genomic breakthroughs are not reaching patients · BMJ Oncology · 2026 · Same journal